Quick Answer
Nuvectis Pharma, Inc. reported Net Income of -$26.44 million for fiscal year 2025.
Nuvectis Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$26.44M -39.2% |
-$19.00M +14.6% |
-$22.26M -16.6% |
-$19.09M -48.1% |
-$12.89M | — |
| Diluted EPS | -$1.32 -18.9% |
-$1.11 +22.4% |
-$1.43 +5.3% |
-$1.51 +50.0% |
-$3.02 | — |
| Total Assets | $31.71M +70.4% |
$18.61M -3.0% |
$19.18M -6.0% |
$20.41M +206.5% |
$6.66M | — |
| Cash and Equivalents | $31.63M +70.7% |
$18.53M -3.1% |
$19.13M -4.3% |
$19.99M +248.2% |
$5.74M | — |
| Stockholders Equity | $18.41M +89.6% |
$9.71M -20.4% |
$12.20M -14.2% |
$14.22M +229.2% |
-$11.01M -109980.0% |
-$10.0K |
| R&D Expense | $18.15M +40.5% |
$12.92M -16.0% |
$15.38M +16.3% |
$13.23M +38.6% |
$9.54M | — |
| Operating Income | -$27.57M -38.9% |
-$19.85M +13.3% |
-$22.90M -19.0% |
-$19.23M -49.2% |
-$12.89M | — |
| Shares Outstanding | 25.68M +31.7% |
19.50M +11.9% |
17.42M +14.7% |
15.19M +237.2% |
4.51M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.46M | -79.7% | -17.8% |
| Diluted EPS | September 30, 2025 | -$0.44 | -83.3% | -46.7% |
| Total Assets | September 30, 2025 | $35.59M | +105.6% | +31.8% |
| Cash and Equivalents | September 30, 2025 | $35.44M | +106.4% | +32.3% |
| Stockholders Equity | September 30, 2025 | $24.01M | +118.5% | +42.3% |
| R&D Expense | September 30, 2025 | $5.77M | +104.8% | +59.8% |
| Operating Income | September 30, 2025 | -$7.79M | -78.8% | -18.2% |
| Shares Outstanding | September 30, 2025 | 25.64M | +35.1% | +7.4% |
- Nuvectis Pharma, Inc. reported Net Income of -$26.44 million for fiscal year 2025.
- Nuvectis Pharma, Inc. showed a decrease of -39.2% in Net Income compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported Diluted EPS of $1.32 per share (loss) for fiscal year 2025.
- Nuvectis Pharma, Inc. showed a decrease of -18.9% in Diluted EPS compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported Total Assets of $31.71 million for fiscal year 2025.
- Nuvectis Pharma, Inc. showed an increase of +70.4% in Total Assets compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported Cash and Equivalents of $31.63 million for fiscal year 2025.
- Nuvectis Pharma, Inc. showed an increase of +70.7% in Cash and Equivalents compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported Stockholders Equity of $18.41 million for fiscal year 2025.
- Nuvectis Pharma, Inc. showed an increase of +89.6% in Stockholders Equity compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported R&D Expense of $18.15 million for fiscal year 2025.
- Nuvectis Pharma, Inc. showed an increase of +40.5% in R&D Expense compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported Operating Income of -$27.57 million for fiscal year 2025.
- Nuvectis Pharma, Inc. showed a decrease of -38.9% in Operating Income compared to the prior fiscal year.
- Nuvectis Pharma, Inc. reported Shares Outstanding of 25.68 million shares for fiscal year 2025.
- Nuvectis Pharma, Inc. showed an increase of +31.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: